How Targeted Cancer Therapies Are Driving the MUC1 Antibody Market Growth According to a newly published market research report by 24LifeSciences, global MUC1 Antibody market is valued at USD 450 million in 2026 and is projected to reach USD 1,066 million by 2034, growing at a compound annual growth rate (CAGR) of 13.4% during the forecast period. MUC1 Antibodies are specialized immunoglobulins targeting Mucin 1, a transmembrane glycoprotein overexpressed in multiple carcinomas including breast, pancreatic, and ovarian cancers. These antibodies enable detection through techniques such as flow cytometry, ELISA, and immunohistochemistry, playing critical roles in cancer research, diagnostics, and therapeutic development. With breast cancer alone accounting for 2.3 million new cases globally in 2022 according to WHO data, the established importance of MUC1 as a biomarker continues to drive market expansion. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3018/muc-antibody-market-market

What Is the Future of the MicroRNA Market? Key Growth Drivers & Insights According to a newly published market research report by 24LifeSciences, global microRNA market was valued at USD 746 million in 2026 and is projected to reach USD 2,409 million by 2034, growing at a compound annual growth rate (CAGR) of 18.7% during the forecast period. MicroRNAs (miRNAs) are small non-coding RNA molecules approximately 22 nucleotides long that play a fundamental role in RNA silencing and post-transcriptional regulation of gene expression. Their critical function in cellular processes, coupled with their stability in bodily fluids, positions them as powerful biomarkers for disease detection, prognosis, and monitoring, particularly in oncology, cardiology, and neurology. The growing integration of miRNAs into advanced molecular diagnostics and therapeutic development pipelines underscores their expanding commercial importance. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8916/microrna-market